Key Morningstar Metrics for Loblaw Companies
- : C$47.00Fair Value Estimate
- : ★Morningstar Rating
- : NoneMorningstar Economic Moat Rating
- : MediumMorningstar Uncertainty Rating
As Canada’s largest food and pharmacy retailer, Loblaw Companies L is working to navigate an increasingly competitive market by leveraging its conventional and discount grocery network as well as Shoppers Drug Mart to capture demand across income levels while competing with globally scaled rivals.
The bottom line: We increase our fair value estimate for no-moat Loblaw to C$47 per share from C$43, reflecting higher sales and operating assumptions, alongside the time value of money. We raise our Uncertainty Rating to Medium from Low and hold our Standard Morningstar Capital Allocation Rating.
- We now forecast 3.8% (from 3.0%) annual sales growth and 6.7% (from 6.2%) average operating margins through fiscal 2035. However, we expect price investment and its mix of discount banners to pressure gross profit, given the intensifying competitive landscape.
- Shares trade roughly 30% above our fair value estimate, as we believe the market is pricing in durable margin expansion and market share gains that we see as unlikely in the face of Loblaw’s global procurement scale deficit.
Long view: In our view, leaning into pharmacy and healthcare services offers Loblaw a necessary margin cushion, but as Canadian consumers’ preference for value-oriented formats continues to grow, long-term value creation will hinge on execution rather than a structural competitive advantage.
- We expect capital expenditures to average 3.4% of sales over the next decade as the firm funds store remodels, supply chain automation, and new unit growth to defend its standing against superiorly scaled mass merchants.
- Ultimately, without the massive cross-border reach of competitors like Walmart and Costco, we forecast Loblaw’s market share to contract 200 basis points to 21.6% by the end of the decade, as its inability to reliably match rivals’ prices takes a toll.
